N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity

Journal of the American College of Cardiology

Volumn 44, Issue 4, 2004, Pages 762-765

  Briguori, Carlo ^a,b   Colombo, Antonio ^b   Airoldi, Flavio ^b   Violante, Anna ^a   Castelli, Alfredo ^b   Balestrieri, Pasquale ^a   Paolo Elia, Pietro ^a   Golia, Bruno ^a   Lepore, Stefano ^a   Riviezzo, Guido ^a   Scarpato, Pierfranco ^a   Librera, Mariateresa ^a   Focaccio, Amelia ^a   Ricciardelli, Bruno ^a  

^a Clinica Mediterranea   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; FENOLDOPAM MESILATE; IODIXANOL;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CREATININE; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENOLDOPAM; FREE RADICAL SCAVENGERS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MALE;

EID: 4143104704     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.04.052     Document Type: Article

References (27)

1. Parfrey PS, Griffiths SM, Barrett, BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-9.
2. G.M. Chertow, C.L. Christiansen, D.P. Cleary Prognostic stratification in critically ill patients with acute renal failure requiring dialysis Arch Intern Med 155 1995 1505 1511
3. McCullough PA, Wolyn R, Rocher LL, Levine RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
4. Weisberg LS, Kurnik PB, Kurnik, BR. Radiocontrast-induced nephropathy in humans. Role of renal vasoconstriction. Kidney Int 1992;41:1408-15.
5. G.L. Bakris, N. Lass, A.O. Gaber, J.D. Jones, J.C. Burnett Jr Radiocontrast medium-induced declines in renal function a role for oxygen free radicals Am J Physiol 258 1990 F115 20
6. R. Baliga, N. Ueda, P.D. Walker, S.V. Shah Oxidant mechanisms in toxic acute renal failure Am J Kidney Dis 29 1997 465 477
7. R. Solomon, C. Werner, D. Mann, J. D'Elia, P. Silva Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents N Engl J Med 331 1994 1416 1420
8. S.J. Schwab, M.A. Hlatky, K.S Pieper Contrast nephrotoxicity a randomized controlled trial of a nonionic and an ionic radiographic contrast agent N Engl J Med 320 1989 149 153
9. B.J. Barrett, E.J. Carlisle Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media Radiology 188 1993 171 178
10. E.P. Steinberg, R.D. Moore, N.R Powe Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography N Engl J Med 326 1992 425 430
11. P. Aspelin, P. Aubry, S.G. Frausson, R. Strasser, R. Willenbrock, K.J. Berg Nephrotoxic effects in high-risk patients undergoing angioplasty N Engl J Med 348 2003 491 499
12. Cigarroa, RG, Lange, RA, Williams, RH, Hillis, LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:64952.
13. M. Tepel, M. Van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, W. Zidek Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine N Engl J Med 343 2000 180 184
14. M.B. Murphy, C. Murray, G.D. Shorten Fenoldopama selective peripheral dopamine-receptor agonist for the treatment of severe hypertension N Engl J Med 345 2001 1548 1557
15. G.L. Bakris, N.A. Lass, D. Glock Renal hemodynamics in radiocontrast medium-induced renal dysfunction a role of dopamine receptors Kidney Int 56 1999 206 210
16. H. Madyoon, L. Croushore, D. Weaver, V. Mathur Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients Cathet Cardiovasc Intervent 53 2001 341 345
17. J.A. Tumlin, A. Wang, P.T. Murray, V.S. Mathur Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion a pilot trial in the prevention of contrast nephropathy Am Heart J 143 2002 894 903
18. A.S. Kini, C.A. Mitre, M. Kim, M. Kamran, D. Reich, S.K. Sharma A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention effect of selective dopamine receptor agonist fenoldopam Cathet Cardiovasc Intervent 55 2002 169 173
19. C. Briguori, A. Colombo, A Violante Standard versus double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity Eur Heart J 25 2004 206 211
20. G.W. Stone, P.A. McCullough, J.A Tumlin Fenoldopam mesylate for the prevention of contrast-induced nephrotoxicity JAMA 290 2003 2284 2291
21. D.W. Cockcroft, M.H. Gault Prediction of creatine clearance from serum creatine Nephron 16 1976 31 41
22. S.H. Hou, D.A. Bushinsky, J.B. Wish, J.J. Cohen, J.T. Harrington Hospital acquired renal insufficiency a prospective study Am J Med 74 1983 243 248
23. M. Tariq, C. Morais, A. Sobki, M. Al Sulaiman, A. Al Khader N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats Nephrol Dial Transplant 14 1999 923 929
24. J. DiMari, J. Megyesi, N. Udvarhelyi, P. Price, R. Davis, R. Safirstein N-acetylcysteine ameliorates ischemic renal failure Am J Physiol 272 1997 F292 8
25. N.P. Andrews, A. Prasad, A.A. Quyymi N-acetylcysteine improves coronary and peripheral vascular function J Am Coll Cardiol 37 2001 117 123
26. R. Birck, S. Krzossok, F. Markowetz, P. Schnulle, F. van der Woude, C. Braun Acetylcysteine for prevention of contrast nephropathy meta-analysis Lancet 362 2003 598 603
27. I. Cotgrease, P. Moldeus, I. Schuppe The metabolism of N-acetylcysteine by human endothelial cells Biochem Pharmacol 42 1991 13 16